USFDA Inspection Concludes at Cohance Lifesciences; Five Observations Received by Company
Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, has received results following a manufacturing facility inspection conducted by the United States Food and Drug Administration (USFDA). The inspection took place at the company's Pashamylaram, Hyderabad facility from July 27, 2026, to August 5, 2026.Upon concluding the review, the Company received a Form FDA 483 detailing five observations relating to its manufacturing operations. Cohance has confirmed that none of these observations pertain to data integrity issues.
Management is committed to maintaining high standards of quality and regulatory compliance. The Company is currently conducting a detailed assessment of the findings and preparing a comprehensive response, which includes necessary corrective and preventive actions (CAPAs). This response will be submitted to the USFDA within the stipulated timeline.
Cohance has stated its commitment to constructively working with the USFDA to ensure the timely and effective resolution of all observations. The Company continues to focus on continuous improvement across its operations and reinforcing robust quality systems that support patient safety and regulatory standards.
COHANCE Stock Price Movement
Today, Cohance Lifesciences Limited saw its stock gain as it closed at ₹429.45, following an ascent of 0.82%. The company recorded a total traded volume of 365,514 shares during the market session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.